公开(公告)号：US20240350603A1

公开(公告)日：2024-10-24

申请号：US18761799

申请日：2024-07-02

Applicant: NantBio, Inc. ,  Nant Holdings IP, LLC ,  Nantomics LLC

Inventor： Kayvan Niazi ,  Nicholas J. Witchey ,  Stephen Charles Benz ,  Shahrooz Rabizadeh

IPC: A61K39/00 ,  G01N33/50 ,  G01N33/569

CPC classification number: A61K39/0011 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/56977 ,  A61K2039/5158 ,  A61K2039/605 ,  A61K2039/6081

Abstract: The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by:



a) obtaining neoepitope sequence data from the tumor of a subject;
b) obtaining immune competent cells;
c) using the neoepitope sequence data to generate a neoepitope presentation system;
d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and
e) quantifying the triggering of the immune response from the contacted immune competent cells.

公开(公告)号：US20240327797A1

公开(公告)日：2024-10-03

申请号：US18577414

申请日：2022-07-08

Applicant: BOOST Pharma ApS

Inventor： Cecilia GÖTHERSTRÖM ,  Magnus WESTGREN ,  Lilian Walther JALLOW

IPC: C12N5/0775 ,  A61K35/28 ,  G01N15/10 ,  G01N15/149 ,  G01N33/569

CPC classification number: C12N5/0668 ,  A61K35/28 ,  G01N15/149 ,  G01N33/56977 ,  G01N2015/1006

Abstract: The present invention relates to a population of fetal mesenchymal stem cells (FMSCs). More specifically the present invention relates to FMSCs capable of differentiating into osteoblasts, as well as methods and uses thereof.

公开(公告)号：US12092635B2

公开(公告)日：2024-09-17

申请号：US18386066

申请日：2023-11-01

Applicant: 10X GENOMICS, INC.

Inventor： Tarjei Sigurd Mikkelsen ,  Eswar Prasad Ramachandran Iyer ,  Andrew Kohlway ,  Luigi Jhon Alvarado Martinez ,  Katherine Pfeiffer ,  Andrew D. Price

IPC: G01N33/532 ,  C07K14/74 ,  C12N15/10 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  C40B30/04 ,  C40B50/06 ,  C40B70/00 ,  G01N33/50 ,  G01N33/53 ,  G01N33/543 ,  G01N33/548 ,  G01N33/569 ,  G01N33/58

CPC classification number: G01N33/532 ,  C07K14/70539 ,  C12N15/1037 ,  C12N15/1055 ,  C12N15/1065 ,  C12N15/1075 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  G01N33/5032 ,  G01N33/505 ,  G01N33/5304 ,  G01N33/5306 ,  G01N33/5308 ,  G01N33/54306 ,  G01N33/54366 ,  G01N33/548 ,  G01N33/56977 ,  G01N33/58 ,  C12N2310/20 ,  C12N2320/10 ,  C12Q2537/164 ,  C12Q2563/179 ,  C12Q2563/185 ,  C12Q2565/1015 ,  C40B30/04 ,  C40B50/06 ,  C40B70/00

Abstract: The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.

公开(公告)号：US20240269179A1

公开(公告)日：2024-08-15

申请号：US18466966

申请日：2023-09-14

Applicant: The Johns Hopkins University

Inventor： Victor E. Velculescu ,  Valsamo Anagnostou

IPC: A61K35/17 ,  A61K39/39 ,  A61P35/00 ,  C07K14/74 ,  C12Q1/68 ,  C12Q1/6869 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/569 ,  G01N33/574 ,  G16B30/00

CPC classification number: A61K35/17 ,  A61K39/39 ,  A61P35/00 ,  C07K14/70539 ,  C12Q1/68 ,  C12Q1/6869 ,  C12Q1/6881 ,  C12Q1/6886 ,  G01N33/56977 ,  G01N33/57484 ,  C12Q2600/106 ,  C12Q2600/156 ,  G16B30/00

Abstract: Disclosed are methods of identifying target epitopes for a tumor of an individual using massively parallel sequencing and analyzing mutant epitopes. Also disclosed are methods of treating a tumor in an individual. Also disclosed are personalized, anti-tumor immunogenic preparations (e.g., personalized, anti-tumor chimeric antigen receptors (CAR) or chimeric antigen receptor T cell (CAR T cell)) customized for an individual cancer patient who initially responded to anti-tumor therapy and later became resistant to the therapy.

公开(公告)号：US12018064B2

公开(公告)日：2024-06-25

申请号：US17396305

申请日：2021-08-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12006349B2

公开(公告)日：2024-06-11

申请号：US17396323

申请日：2021-08-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: A61K38/00 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K14/74 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783 ,  C12N9/64 ,  C12Q1/6886 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569

CPC classification number: C07K14/70539 ,  A01N37/46 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12Q1/6886 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240060968A1

公开(公告)日：2024-02-22

申请号：US18386066

申请日：2023-11-01

Applicant: 10X GENOMICS, INC.

Inventor： Tarjei Sigurd Mikkelsen ,  Eswar Prasad Ramachandran Iyer ,  Andrew Kohlway ,  Luigi Jhon Alvarado Martinez ,  Katherine Pfeiffer ,  Andrew D. Price

IPC: G01N33/532 ,  C07K14/74 ,  C12N15/10 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  G01N33/50 ,  G01N33/53 ,  G01N33/543 ,  G01N33/548 ,  G01N33/569 ,  G01N33/58

CPC classification number: G01N33/532 ,  C07K14/70539 ,  C12N15/1037 ,  C12N15/1055 ,  C12N15/1065 ,  C12N15/1075 ,  C12N15/11 ,  C12N15/85 ,  C12Q1/6804 ,  C12Q1/6806 ,  C12Q1/6818 ,  C12Q1/6827 ,  C12Q1/6881 ,  G01N33/5032 ,  G01N33/505 ,  G01N33/5304 ,  G01N33/5306 ,  G01N33/5308 ,  G01N33/54306 ,  G01N33/54366 ,  G01N33/548 ,  G01N33/56977 ,  G01N33/58 ,  C12N2310/20 ,  C12N2320/10 ,  C12Q2537/164 ,  C12Q2563/179 ,  C12Q2563/185 ,  C12Q2565/1015 ,  C40B30/04

Abstract: The present disclosure provides methods of processing or analyzing a sample. A method for processing a sample may comprise hybridizing a probe molecule to a target region of a nucleic acid molecule (e.g., a ribonucleic acid (RNA) molecule), barcoding the probe-nucleic acid molecule complex, and performing extension, denaturation, and amplification processes. A method for processing a sample may comprise hybridizing first and second probes to adjacent or non-adjacent target regions of a nucleic acid molecule (e.g., an RNA molecule), linking the first and second probes to provide a probe-linked nucleic acid molecule, and barcoding the probe-linked nucleic acid molecule. One or more processes of the methods described herein may be performed within a partition, such as a droplet or well. One or more processes of the methods described herein may be performed on a cell, such as a permeabilized cell.

公开(公告)号：US20230417757A1

公开(公告)日：2023-12-28

申请号：US18343260

申请日：2023-06-28

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Robert Salzler

IPC: G01N33/68 ,  C07K1/22 ,  C07K1/36 ,  C40B30/04 ,  G01N33/569

CPC classification number: G01N33/6842 ,  C07K1/22 ,  C07K1/36 ,  C40B30/04 ,  G01N33/56977 ,  G01N33/6818 ,  G01N33/6848 ,  G01N2333/70539

Abstract: Systems and methods for determining amino acid sequences of peptides that bind to MHC-I or HLA-I complex or MHC-II or HLA-II complex are provided. One embodiment includes isolating peptides from MHC or HLA class I or class II-peptide complexes and adding one or more known labeled peptides of interest to form a sample containing labeled peptides and unlabeled isolated peptides. The method also includes analyzing the sample with an LC-MS/MS system to obtain sequence data of the peptides, and increasing the sensitivity of the LC-MS/MS system when the labeled peptide is detected by the LC-MS/MS system. The method then concludes with determining the amino acid sequence of the unlabeled peptides in an m/z range that includes the m/z of the labeled peptide. The system can be triggered to increase the sensitivity in or near the m/z of the labeled peptide using an algorithm or computer program.

公开(公告)号：US20230348562A1

公开(公告)日：2023-11-02

申请号：US17761151

申请日：2020-09-16

Applicant: King's College London

Inventor： Mark PEAKMAN ,  Johan VERHAGEN ,  Martin EICHMANN

IPC: C07K14/705 ,  A61K31/198 ,  A61K9/14 ,  G01N33/569

CPC classification number: C07K14/70532 ,  A61K31/198 ,  A61K9/146 ,  G01N33/56977 ,  G01N2800/042 ,  G01N2800/50

Abstract: The invention relates to a peptide. The peptide can be used in the therapy or prevention of Type 1 Diabetes (T1D), particularly in a patient with a DR3-DQ2 haplotype. The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the peptide, as well as to a method of identifying T1D-relevant antigen drivers, methods of identifying subjects as being at high-risk of T1D and patients as being suitable for and/or responsive to T1D treatment.

公开(公告)号：US20230296611A1

公开(公告)日：2023-09-21

申请号：US18020436

申请日：2021-08-06

Applicant: INNATE PHARMA

Inventor： MARION BENEZECH ,  ROMAIN REMARK

IPC: G01N33/574 ,  G01N33/569 ,  C07K16/28

CPC classification number: G01N33/57492 ,  G01N33/56977 ,  C07K16/2833 ,  G01N2800/52 ,  C07K2317/31

Abstract: The present disclosure relates to research and diagnostic tools to specifically detect MICA and MICB polypeptides in paraffin embedded tissue samples. The disclosure also relates to methods of using the tools to detect MICA and MICB polypeptides, notably in tumor tissue.